Oncology Medical News about Cardiac, Anthracycline, Breast cancer

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Cardiac toxicity associated with anthracycline-containing chemotherapy in older women with breast cancer
Cancer, 08/17/09

Du XL et al. – Study demonstrates that anthracycline-containing chemotherapy regimens were associated with an increased risk of congestive heart failure, cardiomyopathy, and cardiac dysrhythmias, but not significantly associated with ischemic heart disease or conduction disorder among breast cancer patients.

Methods

A 16 yr follow up study in breast cancer pts to determine the risk of chemotherapy-associated cardiac toxicity, including:
- cardiac dysrhythmia, cardiomyopathy, congestive heart failure,
- ischemic heart disease, and conduction disorders
19,478 women aged >65 diagnosed with BCa in 1991-1997
Incidence density and cumulative incidence of cardiac toxicities were calculated
Time-to-event (cardiac toxicity) analysis was conducted by using the Cox hazard regression model

Results

Excess cumulative incidence of congestive heart failure among pts receiving anthracycline-containing chemotherapy vs pts w/o chemotherapy was 4.7%
After adjusting for patient and tumor characteristics, pts receiving anthracyclines were 25% more likely to have congestive heart failure
Those receiving other agents did not have an elevated risk of developing congestive heart failure
Adjusted risk of cardiomyopathy was 2-fold higher in women who received anthracyclines vs those w/o chemotherapy
Increased risk for developing congestive heart failure, cardiomyopathy, and cardiac dysrhythmias were similar after adjusting for hypertension and diabetes
Risk of ischemic heart disease and conduction disorders were not different among the 3 groups

<< Previous
Micrometastases or isolated tumor cells and the outcome of breast...

Next >>
Expanding role of bisphosphonates in the management of early...